Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Atea Pharmaceuticals is raising $214,999,608.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Jean-Pierre Sommadossi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Atea Pharmaceuticals

Atea is a clinical stage biopharmaceutical company discovering and developing best-in-class therapies to address the unmet medical needs of patients with life-threatening viral diseases. Our medicinal chemistry and virology expertise, bolstered by our collective experience in drug development, enables us to pioneer new advancements in antiviral science. Leveraging the power of our medicinal chemistry expertise and purine nucleotide prodrug platform, we’re able to discover, optimize, and rapidly advance novel drug candidates for viral targets such as SARS-CoV-2.

To learn more about Atea Pharmaceuticals, visit http://www.ateapharma.com/

Contact:
Jean-Pierre Sommadossi, President and Chief Executive Officer
857-204-8109
https://www.linkedin.com/in/jean-pierre-sommadossi-89b7216/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved